Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

Andrea Eisen, Jan Lubinski, Jacek Gronwald, Pal Moller, Henry T. Lynch, Jan Klijn, Charmaine Kim-Sing, Susan L. Neuhausen, Lucy Gilbert, Parviz Ghadirian, Siranoush Manoukian, Gad Rennert, Eitan Friedman, Claudine Isaacs, Eliot Rosen, Barry Rosen, Mary Daly, Ping Sun, Steven A. Narod, Olufunmilayo OlopadeShelly Cummings, Nadine Tung, Fergus Couch, William D. Foulkes, Susan Domchek, Dominique Stoppa-Lyonnet, Ruth Gershoni-Baruch, David Horsman, Teresa Wagner, Howard Saal, Ellen Warner, Wendy Meschino, Kenneth Offit, Amber Trivedi, Mark Robson, Michael Osborne, Dawna Gilchrist, Charis Eng, Jeffrey Weitzel, Wendy McKinnon, Marie Wood, Christine Maugard, Barbara Pasini, Peter Ainsworth, Kevin Sweet, Boris Pasche, Taya Fallen, Beth Karlan, Raluca N. Kurz, Susan Armel, Anna Tulman, Edmond Lemire, Jane Mclennan, Gareth Evans, Tomas Byrski, Tomas Huzarski, Lee Shulman

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.

Original languageEnglish
Pages (from-to)1361-1367
Number of pages7
JournalJournal of the National Cancer Institute
Volume100
Issue number19
DOIs
StatePublished - Oct 2008

Fingerprint

Hormones
Breast Neoplasms
Mutation
Menopause
Odds Ratio
Confidence Intervals
Therapeutics
Estrogens
Ovariectomy
Progesterone
Case-Control Studies
Logistic Models
Population

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Eisen, A., Lubinski, J., Gronwald, J., Moller, P., Lynch, H. T., Klijn, J., ... Shulman, L. (2008). Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. Journal of the National Cancer Institute, 100(19), 1361-1367. https://doi.org/10.1093/jnci/djn313

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. / Eisen, Andrea; Lubinski, Jan; Gronwald, Jacek; Moller, Pal; Lynch, Henry T.; Klijn, Jan; Kim-Sing, Charmaine; Neuhausen, Susan L.; Gilbert, Lucy; Ghadirian, Parviz; Manoukian, Siranoush; Rennert, Gad; Friedman, Eitan; Isaacs, Claudine; Rosen, Eliot; Rosen, Barry; Daly, Mary; Sun, Ping; Narod, Steven A.; Olopade, Olufunmilayo; Cummings, Shelly; Tung, Nadine; Couch, Fergus; Foulkes, William D.; Domchek, Susan; Stoppa-Lyonnet, Dominique; Gershoni-Baruch, Ruth; Horsman, David; Wagner, Teresa; Saal, Howard; Warner, Ellen; Meschino, Wendy; Offit, Kenneth; Trivedi, Amber; Robson, Mark; Osborne, Michael; Gilchrist, Dawna; Eng, Charis; Weitzel, Jeffrey; McKinnon, Wendy; Wood, Marie; Maugard, Christine; Pasini, Barbara; Ainsworth, Peter; Sweet, Kevin; Pasche, Boris; Fallen, Taya; Karlan, Beth; Kurz, Raluca N.; Armel, Susan; Tulman, Anna; Lemire, Edmond; Mclennan, Jane; Evans, Gareth; Byrski, Tomas; Huzarski, Tomas; Shulman, Lee.

In: Journal of the National Cancer Institute, Vol. 100, No. 19, 10.2008, p. 1361-1367.

Research output: Contribution to journalArticle

Eisen, A, Lubinski, J, Gronwald, J, Moller, P, Lynch, HT, Klijn, J, Kim-Sing, C, Neuhausen, SL, Gilbert, L, Ghadirian, P, Manoukian, S, Rennert, G, Friedman, E, Isaacs, C, Rosen, E, Rosen, B, Daly, M, Sun, P, Narod, SA, Olopade, O, Cummings, S, Tung, N, Couch, F, Foulkes, WD, Domchek, S, Stoppa-Lyonnet, D, Gershoni-Baruch, R, Horsman, D, Wagner, T, Saal, H, Warner, E, Meschino, W, Offit, K, Trivedi, A, Robson, M, Osborne, M, Gilchrist, D, Eng, C, Weitzel, J, McKinnon, W, Wood, M, Maugard, C, Pasini, B, Ainsworth, P, Sweet, K, Pasche, B, Fallen, T, Karlan, B, Kurz, RN, Armel, S, Tulman, A, Lemire, E, Mclennan, J, Evans, G, Byrski, T, Huzarski, T & Shulman, L 2008, 'Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers', Journal of the National Cancer Institute, vol. 100, no. 19, pp. 1361-1367. https://doi.org/10.1093/jnci/djn313
Eisen, Andrea ; Lubinski, Jan ; Gronwald, Jacek ; Moller, Pal ; Lynch, Henry T. ; Klijn, Jan ; Kim-Sing, Charmaine ; Neuhausen, Susan L. ; Gilbert, Lucy ; Ghadirian, Parviz ; Manoukian, Siranoush ; Rennert, Gad ; Friedman, Eitan ; Isaacs, Claudine ; Rosen, Eliot ; Rosen, Barry ; Daly, Mary ; Sun, Ping ; Narod, Steven A. ; Olopade, Olufunmilayo ; Cummings, Shelly ; Tung, Nadine ; Couch, Fergus ; Foulkes, William D. ; Domchek, Susan ; Stoppa-Lyonnet, Dominique ; Gershoni-Baruch, Ruth ; Horsman, David ; Wagner, Teresa ; Saal, Howard ; Warner, Ellen ; Meschino, Wendy ; Offit, Kenneth ; Trivedi, Amber ; Robson, Mark ; Osborne, Michael ; Gilchrist, Dawna ; Eng, Charis ; Weitzel, Jeffrey ; McKinnon, Wendy ; Wood, Marie ; Maugard, Christine ; Pasini, Barbara ; Ainsworth, Peter ; Sweet, Kevin ; Pasche, Boris ; Fallen, Taya ; Karlan, Beth ; Kurz, Raluca N. ; Armel, Susan ; Tulman, Anna ; Lemire, Edmond ; Mclennan, Jane ; Evans, Gareth ; Byrski, Tomas ; Huzarski, Tomas ; Shulman, Lee. / Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. In: Journal of the National Cancer Institute. 2008 ; Vol. 100, No. 19. pp. 1361-1367.
@article{38d0f59e18944f608419c69dfa276249,
title = "Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers",
abstract = "Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95{\%} confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95{\%} CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95{\%} CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95{\%} CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.",
author = "Andrea Eisen and Jan Lubinski and Jacek Gronwald and Pal Moller and Lynch, {Henry T.} and Jan Klijn and Charmaine Kim-Sing and Neuhausen, {Susan L.} and Lucy Gilbert and Parviz Ghadirian and Siranoush Manoukian and Gad Rennert and Eitan Friedman and Claudine Isaacs and Eliot Rosen and Barry Rosen and Mary Daly and Ping Sun and Narod, {Steven A.} and Olufunmilayo Olopade and Shelly Cummings and Nadine Tung and Fergus Couch and Foulkes, {William D.} and Susan Domchek and Dominique Stoppa-Lyonnet and Ruth Gershoni-Baruch and David Horsman and Teresa Wagner and Howard Saal and Ellen Warner and Wendy Meschino and Kenneth Offit and Amber Trivedi and Mark Robson and Michael Osborne and Dawna Gilchrist and Charis Eng and Jeffrey Weitzel and Wendy McKinnon and Marie Wood and Christine Maugard and Barbara Pasini and Peter Ainsworth and Kevin Sweet and Boris Pasche and Taya Fallen and Beth Karlan and Kurz, {Raluca N.} and Susan Armel and Anna Tulman and Edmond Lemire and Jane Mclennan and Gareth Evans and Tomas Byrski and Tomas Huzarski and Lee Shulman",
year = "2008",
month = "10",
doi = "10.1093/jnci/djn313",
language = "English",
volume = "100",
pages = "1361--1367",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "19",

}

TY - JOUR

T1 - Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

AU - Eisen, Andrea

AU - Lubinski, Jan

AU - Gronwald, Jacek

AU - Moller, Pal

AU - Lynch, Henry T.

AU - Klijn, Jan

AU - Kim-Sing, Charmaine

AU - Neuhausen, Susan L.

AU - Gilbert, Lucy

AU - Ghadirian, Parviz

AU - Manoukian, Siranoush

AU - Rennert, Gad

AU - Friedman, Eitan

AU - Isaacs, Claudine

AU - Rosen, Eliot

AU - Rosen, Barry

AU - Daly, Mary

AU - Sun, Ping

AU - Narod, Steven A.

AU - Olopade, Olufunmilayo

AU - Cummings, Shelly

AU - Tung, Nadine

AU - Couch, Fergus

AU - Foulkes, William D.

AU - Domchek, Susan

AU - Stoppa-Lyonnet, Dominique

AU - Gershoni-Baruch, Ruth

AU - Horsman, David

AU - Wagner, Teresa

AU - Saal, Howard

AU - Warner, Ellen

AU - Meschino, Wendy

AU - Offit, Kenneth

AU - Trivedi, Amber

AU - Robson, Mark

AU - Osborne, Michael

AU - Gilchrist, Dawna

AU - Eng, Charis

AU - Weitzel, Jeffrey

AU - McKinnon, Wendy

AU - Wood, Marie

AU - Maugard, Christine

AU - Pasini, Barbara

AU - Ainsworth, Peter

AU - Sweet, Kevin

AU - Pasche, Boris

AU - Fallen, Taya

AU - Karlan, Beth

AU - Kurz, Raluca N.

AU - Armel, Susan

AU - Tulman, Anna

AU - Lemire, Edmond

AU - Mclennan, Jane

AU - Evans, Gareth

AU - Byrski, Tomas

AU - Huzarski, Tomas

AU - Shulman, Lee

PY - 2008/10

Y1 - 2008/10

N2 - Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.

AB - Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.

UR - http://www.scopus.com/inward/record.url?scp=53249097506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249097506&partnerID=8YFLogxK

U2 - 10.1093/jnci/djn313

DO - 10.1093/jnci/djn313

M3 - Article

C2 - 18812548

AN - SCOPUS:53249097506

VL - 100

SP - 1361

EP - 1367

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 19

ER -